Regeneron Pharmaceuticals
734,81 $Variazione rispetto alla chiusura precedente: −3,09%Variazione assoluta: −23,46 $
Ultime notizie
Titoli nella lingua originale della fonte.
- Friday Five: Sanofi and Regeneron (re)partner up in the face of Dupixent's patent cliff, AstraZeneca invests $2B in Summit, Lilly delivers more weight loss wins…and more (si apre in una nuova scheda)
- Regeneron (REGN) Stock May Be Underpriced Despite Its $1b Alliance Expansion (si apre in una nuova scheda)
- Why Regeneron (REGN) Stock Is Trading Lower Today (si apre in una nuova scheda)
- Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day (si apre in una nuova scheda)
- Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion (si apre in una nuova scheda)
- Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent (si apre in una nuova scheda)
- Sanofi To Pay Regeneron Up To $8B In Immunology Alliance (si apre in una nuova scheda)
- Sanofi And Regeneron Expand Immunology Alliance In Deal Worth Up To $8 Billion (si apre in una nuova scheda)
- Regeneron Pharmaceuticals (NDQ:REGN): Is This Dark Horse The TSMC Of The Pharmaceutical Sector? (si apre in una nuova scheda)
- Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $930.00 (si apre in una nuova scheda)
- Regeneron Pharmaceuticals (REGN) Reports Promising Ubamatamab Tr (si apre in una nuova scheda)
- Regeneron Pharmaceuticals (REGN) Reports Promising Phase 1/2 Tri (si apre in una nuova scheda)
- Regeneron posts trial data for ovarian cancer therapy (REGN:NASDAQ) (si apre in una nuova scheda)
- Regeneron Pharmaceuticals (REGN) Unveils Positive Phase 2 COURAG (si apre in una nuova scheda)
- Regeneron, Sanofi Expand Alliance with $1 Billion Upfront, 4 Antibodies (si apre in una nuova scheda)
- Regeneron Pharmaceuticals Says Ubamatamab Show 73% Objective Response Rate & 11-Month Median PFS In LGSOC Patients (si apre in una nuova scheda)
- Sanofi Deepens 20-Year Drug Development Pact With Regeneron, Pledges Up to $8 Billion (si apre in una nuova scheda)
- Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies - Slideshow (NASDAQ:REGN) 2026-10-01 (si apre in una nuova scheda)
- Regeneron and Sanofi Expand Antibody Alliance with Four New Drugs (si apre in una nuova scheda)
- Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal (si apre in una nuova scheda)
- Argus Research Upgrades Regeneron Pharmaceuticals(REGN.US) to Buy Rating, Announces Target Price $850 (si apre in una nuova scheda)
- Sanofi, Regeneron expand partnership after Dupixent success (si apre in una nuova scheda)
- Sanofi pays $1B upfront to expand immunology deal with Regeneron (si apre in una nuova scheda)
- Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Argus (si apre in una nuova scheda)
- Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecasts (si apre in una nuova scheda)
- Breakingviews - COMMENTARY: Sanofi’s Regeneron fix requires extra shot of M&A (si apre in una nuova scheda)
- Sanofi and Regeneron expand immunology partnership to the tune of $8bn (si apre in una nuova scheda)
- Sanofi pays $1B upfront to expand Regeneron alliance beyond Dupixent (si apre in una nuova scheda)
- Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D (si apre in una nuova scheda)
- Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies (si apre in una nuova scheda)